A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO studyÖ. Türeci, Martin Schüler, Florian Lordick et al.|Annals of Oncology|2019Cited by 244
Clonal haematopoiesis of indeterminate potential and mortality in coronary artery diseaseMoritz von Scheidt, Nicholas J. Leeper, Shaunak Adkar et al.|European Heart Journal|2025Cited by 14